Results 41 to 50 of about 6,966 (163)

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

Medicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva, Alessandra Aiello, Tonino Alonzi, M. Alice Carvalho, Vladimir Finger, Delia Goletti, Sven Hoffner, Yousra Kherabi, Jan Korabecny, Julia Kulczyńska, Agnieszka Kyzioł, Alicia Lacoma, Filomena Martins, Zorica Nanovic, Sepideh Hosseiniporgham, Martina Hrast Rambaher, Leonardo Antonio Sechi, Daria Smalchuk, Grażyna Stochel, Lydia Tabernero, Nancy L. Tateosian, Violeta Valcheva, Anamarija Zega, Mafalda Sarraguça   +23 more
wiley   +1 more source

Novel and emerging antimicrobial strategies in the management of oral infections

Periodontology 2000, EarlyView.
Abstract Background Antibiotics marked a pivotal turning point in human civilization, enhancing social interactions and extending human life expectancy. In addition to their success in treating systemic infectious diseases, they have significantly improved periodontal treatment outcomes as an adjunct therapy.
Ozge Unlu, Nil Yakar, Alpdogan Kantarci
wiley   +1 more source

Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis

Frontiers in Medicine, 2023
Chronic prostatitis (CP) is a common inflammatory condition of the prostate that is estimated to effect 2%–10% of the world’s male population. It can manifest as perineal, suprapubic, or lower back pain and urinary symptoms occurring with either ...
Roy H. Stevens, Hongming Zhang, Michal Kajsik, Michal Kajsik, Rafał Płoski, Malgorzata Rydzanicz, Peter Sabaka, Stanislav Šutovský   +7 more
doaj   +1 more source

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3448-3459, October 2026.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

A two-component, multimeric endolysin encoded by a single gene

, 2015
"Bacteriophage endolysins are bacterial cell wall degrading enzymes whose potential to fight bacterial infections has been intensively studied. Endolysins from Gram-positive systems are typically described as monomeric and as having a modular structure ...
Leandro, Clara, Pimentel, Madalena, Garcia, Miguel, São-José, Carlos, Velours, Christophe, Proença, Daniela   +5 more
core   +1 more source

Endolysin Regulation in Phage Mu Lysis

mBio, 2022
Bacteriophage Mu is a paradigm coliphage studied mainly because of its use of transposition for genome replication. However, in extensive nonsense mutant screens, only one lysis gene has been identified, the endolysin gp22.
Jake S. Chamblee, Jolene Ramsey, Yi Chen, Lori T. Maddox, Curtis Ross, Kam H. To, Jesse L. Cahill, Ry Young   +7 more
doaj   +1 more source

Lytic activity of Ts2631 endolysin variants.

, 2015
Substitutions were generated by site-directed mutagenesis of a clone of Ts2631 endolysin in the pET15b vector (Novagen) using oligonucleotides with a degenerate sequence at the target codon.
Slawomir Dabrowski (796496), Gudmundur O. Hreggvidsson (6607), Janusz M. Bujnicki (6998), Lukasz P. Kozlowski (796495), Sigridur Hjörleifsdottir (5649904), Sigurlaug Skírnisdottir (5665291), Jakob K. Kristjansson (6609), Olafur H. Fridjonsson (6602), Joanna Makowska (796494), Audur Thorisdottir (6597), Anna-Karina Kaczorowska (796492), Magdalena Plotka (796491), Agnieszka Morzywolek (796493), Tadeusz Kaczorowski (796497)   +13 more
core   +1 more source

8.EXTRACTION, PURIFICATION AND THERAPEUTIC USE OF BACTERIOPHAGE ENDOLYSIN AGAINST MULTI-DRUG RESISTANT PSEUDOMONAS AERUGINOSA: AN IN-VITRO AND IN-VIVO STUDY

The Iraqi Journal of Medical Sciences, 2019
Background: Persistent infection with multidrug resistant Pseudomonas aeruginosa (P. aeruginosa) represents a real problem for health care providers. Bacteriophage lytic enzymes or lysins are highly evolved molecules that have been specifically developed
Mohammed R. Ali, Shurooq R. Kadhim, Ahmed S. Abdulamir   +2 more
doaj   +6 more sources

Genomic and Phenotypic Characterization of Two Novel Enterobacter Phages With EDTA‐Enhanced Antibiofilm Activity

MicrobiologyOpen, Volume 15, Issue 5, October 2026.
Two novel lytic Enterobacter phages, HHH and RZH, displayed targeted antibiofilm activity against MDR Enterobacter cloacae complex biofilms when combined with EDTA. Activity was strongest within a narrow low‐millimolar EDTA window, reducing biofilm biomass and viable burden, while higher EDTA concentrations shifted the interaction towards antagonism ...
Kashif Haq, Zac Newland‐Smith, Martin Figgit, David Lee, Kwabena Duedu   +4 more
wiley   +1 more source

PHAGE COCKTAILS AGAINST HIGHLY MULTI-DRUG RESISTANT ACINETOBACTER BAUMANII

The Iraqi Journal of Medical Sciences, 2018
Background:Phage therapy is a potential alternative treatment for infections caused by many bacterial species such as Acinetobacter baumannii (A.
Hayder Jasim, Ahmad Abdul-Ameer
doaj   +1 more source